Damien Bové interview with BusinessCann, CBD publication

Damien Bové interview with BusinessCann, CBD publication discusses Novel Food application studies

Damien Bové interview with BusinessCann, a respected CBD publication, discusses the European Industrial Hemp Association (EIHA) response to criticisms over its Novel Food application studies.When asked about recent biomedical research actives undertaken by the EIHA, Damien told BusinessCann that ‘This was not an adverse event, but it could lead to adverse events down the line. So it’s an observed event.’ There is a ‘pretty significant margin of error’ for testing in rats in terms of how it relates to human metabolism, and that pharmaceutical studies often test on more than one animal ‘to see if you get the same effect’.You can read the full interview with BusinessCann at: https://businesscann.com/eiha-responds-to-criticisms-over-its-novel-food-applications-tox-studies/ 

Affordable, quality testing in our accredited UK lab

To speak to our expert, friendly team, about novel foods or anything else, please phone +44(0)1302 986 088 or email hello@adactmedical.com today.We look forward to speaking with you soon. Our CBD compliance and quality services:

Previous
Previous

Belgium propose new vaping regulations

Next
Next

Merry Christmas from ADACT